Added to YB: 2026-03-25
Pitch date: 2026-01-24
CRBP [bullish]
Corbus Pharmaceuticals Holdings, Inc.
-5.32%
current return
Author Info
No bio for this author
Company Info
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity.
Market Cap
$152.5M
Pitch Price
$8.64
Price Target
13.25 (+57%)
Dividend
N/A
EV/EBITDA
0.11
P/E
-1.46
EV/Sales
N/A
Sector
Biotechnology
Category
value
Corbus Pharmaceuticals Holdings, Inc. - $CRBP
CRBP: 3 uncorrelated programs (oncology/obesity) at negative EV. $161M mkt cap vs $178M cash, $15M/Q burn. CRB-701 Nectin-4 ADC shows 47.6% ORR in HNSCC (vs Padcev 23.9%), 55.6% in mUC, lower toxicity; mid-2026 durability data critical for pivotal trial. CRB-913 CB1 inverse agonist 2.9% pbo-adj weight loss in 7-day MAD, cleaner neuropsych profile vs Novo's monlunabant; 240-patient Canyon-1 reads summer 2026. CRB-601 anti-⍺vβ8 mAb P1 data Q1 2026. Financed at $13.25 vs $8.65 today.
Read full article (7 min)